0001209191-18-022389.txt : 20180402 0001209191-18-022389.hdr.sgml : 20180402 20180402163655 ACCESSION NUMBER: 0001209191-18-022389 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180322 FILED AS OF DATE: 20180402 DATE AS OF CHANGE: 20180402 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: LUDLAM WILLIAM CENTRAL INDEX KEY: 0001736280 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37500 FILM NUMBER: 18729414 MAIL ADDRESS: STREET 1: C/O CHIASMA, INC. STREET 2: 460 TOTTEN POND ROAD, SUITE 530 CITY: WALTHAM STATE: MA ZIP: 02451 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CHIASMA, INC CENTRAL INDEX KEY: 0001339469 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 460 TOTTEN POND ROAD STREET 2: SUITE 530 CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 617-928-5300 MAIL ADDRESS: STREET 1: 460 TOTTEN POND ROAD STREET 2: SUITE 530 CITY: WALTHAM STATE: MA ZIP: 02451 FORMER COMPANY: FORMER CONFORMED NAME: CHIASMA INC DATE OF NAME CHANGE: 20050922 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2018-03-22 0 0001339469 CHIASMA, INC CHMA 0001736280 LUDLAM WILLIAM C/O CHIASMA, INC. 460 TOTTEN POND ROAD SUITE 530 WALTHAM MA 02451 0 1 0 0 See Remarks Common Stock 5124 D Stock Option (Right to Buy) 28.40 2025-09-10 Common Stock 14084 D Stock Option (Right to Buy) 28.40 2025-09-10 Common Stock 45916 D Stock Option (Right to Buy) 9.93 2026-02-10 Common Stock 969 D Stock Option (Right to Buy) 9.93 2026-02-10 Common Stock 14531 D Stock Option (Right to Buy) 2.60 2026-10-25 Common Stock 25003 D Stock Option (Right to Buy) 2.60 2026-10-25 Common Stock 74997 D Stock Option (Right to Buy) 1.52 2028-02-23 Common Stock 52011 D Stock Option (Right to Buy) 1.52 2028-02-23 Common Stock 18189 D This option vests over a four-year period at a rate of twenty-five percent (25%) on August 26, 2016 and 36 equal monthly installments thereafter. This option vests over a four-year period at a rate of twenty-five percent (25%) on February 10, 2017 and in 12 equal quarterly installments thereafter. This option vests over a four-year period at a rate of twenty-five percent (25%) on October 25, 2017 and in 12 equal quarterly installments thereafter. This option vests over a four-year period in 16 equal quarterly installments, the first such installment vesting on May 23, 2018. This option vests as follows: (i) 40% of such award will be earned upon FDA acceptance of a new drug application ("NDA") for Mycapssa, of which amount 50% will be immediately vested and 50% will vest upon the one year anniversary of such acceptance; and (ii) 60% of such award will be earned upon FDA approval of such NDA, of which amount 50% will be immediately vested and 50% will vest upon the one year anniversary of such approval. Title: Senior Vice President, Clinical and Medical Affairs /s/ William Ludlam 2018-04-02